Global Pharmaceutical Company

  • Eigen X was engaged to provide project management, business analysis, testing, and development support for a large scale BI transformation for a Fortune 100 Pharmaceutical company. Oracle / Tableau / Teradata — Our consultants are leading multiple cross-functional teams as part of this complex project transitioning the client from an Oracle data warehouse to Teradata and implementing Tableau ( and Cognos BI reports for their PMO and every function within their research and development sector.
  •  The Life Sciences Industry is a broad sector including Pharmaceutical, Medical Products and Bio-Technology Industries along with associated service providers and supply-chain partners.   Companies across each of these sectors, and associated sectors such as Healthcare and High Technology, are becoming increasingly interrelated.The Life Sciences Industry as a whole is facing extreme pressures to reduce costs while having to managing an increasingly complex business environment.  The Food and Drug Administration, Health Management Organizations and Group Purchasing Organizations are just a few examples of external sources applying pressures to this industry.

    Increased competition and price pressures will reward Life Sciences companies that focus on creating world class Sales and Marketing Organizations, rather than relying solely on R&D success.

    Some of the main challenges impacting the Life Sciences Industry today include:

    • Maximizing return in revenue on marketing dollars spent.
    • Increasingly complex purchasing decision environment based on the changes in the healthcare provider and payer market and the impact of new buying organizations.
    • Merger and acquisition activities resulting in the need to consolidate and integrate Sales Forces, distribution networks and back-office environments.
    • Keeping abreast of and complying with changing federal regulations such as CFR 21 Part 11.
    • Increasing need for end consumer feedback will drive the need for greater outbound telecommunication capabilities.
    • Cooperative sales agreements and alliances will drive the need for improved measurement and audit capabilities as well as flexible infrastructure and systems.
    • Managing constantly changing business process and new technology requirements in a validated environment.
    • Navigating the complex data and document management issues associated with R&D efforts, clinical trials and FDA submissions.
    • Managing an already complex supply chain and distribution channel, which is becoming more complex based on consolidation of major players, new entrants and international concerns.

    In addition, Life Sciences companies are facing the same challenges related to the current economic conditions as companies within other industries.

    Some of these challenges include:

    • Increasing pressures to manage the total cost of ownership of technology.
    • Improving employee efficiencies and managing headcount.
    • Change in legal environment has resulted in decrease time to regain initial investment and profits.
    • Increased number of drug recalls has prompted the industry to develop comprehensive validation under threat of possible inquiry into the systems that produced initial data.
    • Training of FDA investigators in computer validation and 21CFR Part 11 are resulting in an increased number of computer system inspections.
    • Global trend in increased automation and electronic information transfer may result in increased regulatory enforcement focused on computer system integrity.
    • Increasing pressures to reduce the cost of procuring direct and indirect materials and services by the organization.
    • Protecting critical technology assets and proprietary data against an increasing cyber-security threat.